.jpeg)
Target of Erdafitinib
Erdafitinib (Erdafitinib) is a kinase inhibitor based on binding and inhibiting the enzymatic activities of FGFR1, FGFR2, FGFR3 and FGFR4 in vitro. It also binds to RET, CSF1R, PDGFRA, PDGFRB, FLT4, KIT and VEGFR2. Erdafitinib inhibits FGFR phosphorylation and signaling and reduces cell viability in cell lines expressing genetic alterations in FGFR, including point mutations, amplifications, and fusions. Erdafitinib has demonstrated antitumor activity in FGFR-inhibitory cell lines and xenograft models derived from tumor types, including bladder cancer.
[ 免责声明 ] 本页面内容来自公开渠道（如FDA官网、Drugs官网、原研药厂官网等），仅供持有医疗专业资质的人员用于医学药学研究参考，不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市，不适用于中国境内销售和使用。如需治疗，请咨询正规医疗机构。本站不提供药品销售或代购服务。
